Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

Celecoxib

  • You have access
    The Combination of Auranofin and Celecoxib Suppresses Local Synovial Sarcoma Progression In Vivo
    HIDEYUKI KINOSHITA, SEIKO KINOSHITA, HIROTO KAMODA, YOKO HAGIWARA, SEIJI OHTORI and TSUKASA YONEMOTO
    Anticancer Research June 2024, 44 (6) 2453-2458; DOI: https://doi.org/10.21873/anticanres.17052
  • You have access
    Combined Auranofin and Celecoxib Suppresses the Local Progression and Pulmonary Metastases of Osteosarcoma In Vivo
    HIDEYUKI KINOSHITA, SEIKO KINOSHITA, HIROTO KAMODA, YOKO HAGIWARA, SEIJI OHTORI and TSUKASA YONEMOTO
    Anticancer Research March 2024, 44 (3) 1045-1049; DOI: https://doi.org/10.21873/anticanres.16899
  • You have access
    Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer
    KUNIHIKO KOBAYASHI, KYOICHI KAIRA and HIROSHI KAGAMU
    Anticancer Research September 2020, 40 (9) 5309-5311; DOI: https://doi.org/10.21873/anticanres.14537
  • You have access
    Nonsteroidal Anti-inflammatory Drugs Modulate Gene Expression of Inflammatory Mediators in Oral Squamous Cell Carcinoma
    DANIELLA MORAES ANTUNES, MARIA FERNANDA SETÚBAL DESTRO RODRIGUES, DOUGLAS MAGNO GUIMARÃES, CARINA MAGALHÃES ESTEVES DUARTE, LUCYENE MIGUITA, LUCIANA CORRÊA, ANA PAULA LIGEIRO DE OLIVEIRA, KRISTIANNE PORTA SANTOS FERNANDES and FABIO DAUMAS NUNES
    Anticancer Research May 2019, 39 (5) 2385-2394; DOI: https://doi.org/10.21873/anticanres.13356
  • You have access
    Effects of Combined Treatment with Vitamin D and COX2 Inhibitors on Breast Cancer Cell Lines
    MICHAEL FRIEDRICH, KATHRIN REICHERT, ALENA WOESTE, STEPHAN POLACK, DOROTHEA FISCHER, FRIEDERIKE HOELLEN, ACHIM RODY, FRANK KÖSTER and MARC THILL
    Anticancer Research February 2018, 38 (2) 1201-1207;
  • You have access
    Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice
    RUI M. GIL DA COSTA, RITA ARAÚJO, JOANA M.O. SANTOS, MARA FERNANDES, TIAGO NETO, HUGO SOUSA, JOANA RIBEIRO, MARGARIDA M.S.M. BASTOS, PAULA A. OLIVEIRA, DIOGO CARMO, FÁTIMA CASACA, SANDRA SILVA, CARLOS LOPES and RUI MEDEIROS
    Anticancer Research June 2017, 37 (6) 2913-2918;
  • You have access
    Co-treatment with Celecoxib or NS398 Strongly Sensitizes Resistant Cancer Cells to Antimitotic Drugs Independent of P-gp Inhibition
    JONG SEUNG LIM, YUJIN PARK, BYUNG MU LEE, HYUNG SIK KIM and SUNGPIL YOON
    Anticancer Research October 2016, 36 (10) 5063-5070;
  • You have access
    Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine
    TOKUNBO YEROKUN and LEYTE L. WINFIELD
    Anticancer Research December 2015, 35 (12) 6419-6424;
  • You have access
    Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment
    JOHANNES KERSCHBAUMER, FRANZISKA ANNA SCHMIDT, ASTRID ELLEN GRAMS, MARTHA NOWOSIELSKI, DANIEL PINGGERA, KONSTANTIN ROBERT BRAWANSKI, ONDRA PETR, CLAUDIUS THOMÉ, JOCHEN TUETTENBERG, MARCEL SEIZ and CHRISTIAN FRANZ FREYSCHLAG
    Anticancer Research September 2015, 35 (9) 4955-4960;
  • You have access
    Effect of Celecoxib on Survival of Mobile Tongue Cancer
    DOH YOUNG LEE, JAE HYUN LIM, YOON JOONG KIM, SEONG DONG KIM, SEOK-WOO PARK, SEONG KEUN KWON, J. HUN HAH, TACK-KYUN KWON, KWANG HYUN KIM, YOUNG HO KIM and MYUNG-WHUN SUNG
    Anticancer Research July 2015, 35 (7) 4235-4241;

Pages

  • Next
  • 1
  • 2
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire